Overview

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate several interventions given to participants with severe asthma. Interventions are administered in a crossover manner with 16-week treatment periods followed by 8 to 16 week washout.
Phase:
Phase 2
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Broncho-Vaxom
Imatinib Mesylate